Skip to content
Global markets · Independent coverage Follow a hub and receive new coverage by email.

NYSE:ANVS

Annovis Bio (ANVS) Soars After New Parkinson’s Biomarker Data Show Buntanetap Halts Cognitive Decline – November 17, 2025

On November 17, 2025, Annovis Bio, Inc. released new Phase 3 data in early Parkinson’s disease showing that its lead drug candidate buntanetap halted cognitive decline and improved key Alzheimer’s-related biomarkers in a significant…

10 min read
BiotechnologyNYSE:ANVS

Company hubNYSE:ANVS

ANVS (ANVS) Stock News & Analysis

Follow the latest ANVS (ANVS) company news, earnings coverage and investor analysis from TechStock².

Save this hub to your TS2 Signalbook account.
Latest update
Articles in this hub
1
Last 30 days
0

What investors are watching

  • Earnings, guidance and financial performance
  • Valuation, trading activity and market sentiment
  • Strategy, catalysts and company-specific risks

All coverage

NYSE:ANVS

1 articles